Introduction: Hematopoietic stem cells (HSCs) are used in the treatment of many malignant and non-malignant diseases to replace or rebuild a patient's hematopoietic system. Objective: To evaluate the purity, recovery, viability of CD34+ cells selected from harvested peripheral blood stem cells using the CliniMACS system (as well as the T cell content of aphereses product. Subject and method: Healthy donor was mobilised with granulocyte colony stimulating factor (G-CSF). A total of leukaphereses for peripheral blood stem cell was harvested using the Optial Spectra cell separator (Terumo, Japan). The harvested PBSC were then positively selected for CD34+ cells using the CliniMACS divice (Miltenyi Biotech, Germany). Result: Total of leukaphereses products from pre-selection using CliniMACS was 30900 x 106cell, pre-selection total CD34+ cell count of the aphereses products was 118 x 106 cell. The post-selection total of leukapheresis products using CliniMACS was 95 x 106 cell, total CD34+ cell count was 84 x 106 cell with the recovery was 71 percent and the purity of product was 88 percent. Viability of CD34+ was tested with 7AAD using Facs Canto II with pre and post selection viabilities of 96 percent. Total CD3 cell count reduced from 61 percent pre-selection to 12 percent post-selection. Conclusion: Positive selection of CD34+ cells using magnetic separation technology by CliniMACS device did not affect the viability of selected cells, and result in low T-cell content stem cell with acceptable purity and recovery for autologous and allogenic stem cell transplantation.
- Đăng nhập để gửi ý kiến